Candida biofilm infections pose an increasing threat in the health care setting due to the drug resistance associated with this lifestyle. Several mechanisms underlie the resistance phenomenon. In Candida albicans, one mechanism involves drug impedance by the biofilm matrix linked to ␤-1,3 glucan. Here, we show this is important for other Candida spp. We identified ␤-1,3 glucan in the matrix, found that the matrix sequesters antifungal drug, and enhanced antifungal susceptibility with matrix ␤-1,3 glucan hydrolysis.
thoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt] optical density (OD) of 1.42 for C. albicans and 1.40 for the non-albicans group after 24 h of incubation. For matrix composition analysis, biofilms were grown for 48 h using 1-liter roller bottles. Matrix was isolated using water bath sonication and vortexing as previously described (19) . A ␤-1,3 glucan enzyme-linked immunosorbent assay (ELISA) was performed on three biologic replicates, and assays were completed in triplicate for each strain as previously detailed. Matrix ␤-1,3 glucan was normalized by matrix dry weight and expressed as ng/mg matrix. As shown in Fig. 1A , the ␤-1,3 glucan polymer was identified in the biofilm matrix of each Candida strain tested. The concentrations of this polysaccharide among the species were relatively similar.
We utilized a 6-well plate format for assessment of antifungal drug biofilm penetration using [H 3 ]fluconazole as described previously (13, 19) . Briefly, mature biofilms (24 h of incubation) were washed twice with sterile water followed by exposure to a total of 8.48 ϫ 10 5 cpm of [H 3 ]fluconazole in RPMI-MOPS medium. Biofilms were incubated for 30 min at 37°C and then chased with 20 M unlabeled fluconazole in medium. The fluconazole content was measured in intact biofilms, isolated matrix, cell wall, and cell cytoplasm by scintillation counting. Assays were performed in triplicate for each Candida isolate. Consistent with previous findings in C. albicans (13, 19) , the majority of [H 3 ]fluconazole is present in the extracellular matrix for each of these species, with very little or no drug found intracellularly or in the cell wall (Fig. 1B) .
We next determined the effect of matrix ␤-1,3 glucan hydrolysis on biofilm susceptibility to fluconazole. Using a 96-well plate format, biofilm cell metabolic activity was assayed following exposure to fluconazole and ␤-1,3 glucanase alone and in combination using a tetrazolium salt XTT reduction assay (20) (21) (22) (23) . Briefly, after 24 h of biofilm growth, medium was replaced by fresh RPMI-MOPS with dilutions of fluconazole at 1 mg/ml, ␤-1,3 glucanase (Zymolyase 20T; MP Biomedicals) at 0.7 U/ml, or a combination of the two. The ␤-1,3 glucanase concentration was chosen based upon our previous studies with C. albicans demonstrating synergy with fluconazole and no effect on cell viability for the enzyme alone (12, 19) . Experiments were performed in triplicate. Drug effect is expressed at the percent biofilm reduction relative to growth of untreated controls. The statistical significance of differences among therapies was determined using analysis of variance (ANOVA). Similar to previous reports, fluconazole alone exhibited minimal activity against biofilms for each strain and species (12, 19) . The low concentration of ␤-1,3 glucanase also produced little change in cell metabolic activity. However, fluconazole caused marked biofilm reduction in the presence of the ␤-1,3 glucanhydrolyzing enzyme. This effect was observed for all strains tested (Fig. 1C) .
The results of the present study with non-albicans Candida species are similar to those from C. albicans, which demonstrate the contribution of biofilm matrix ␤-1,3 glucan for the antifungal drug resistance phenomenon linked to this common infection lifestyle (12) (13) (14) . The relative impact of the mechanism for these other common Candida species appears congruent with that shown for C. albicans based upon comparable concentrations of matrix ␤-1,3 glucan, antifungal drug sequestration, and influence of ␤-1,3 glucanase treatment on fluconazole efficacy. The prevalence of these non-albicans Candida species continues to rise. Insight to the mechanisms responsible for resistance to therapy is critical for design of new treatment strategies. The present study suggests that drug development targeting matrix ␤-1,3 glucan may potentiate the activity of the currently available antifungal option.
